Condensed Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Operating activities
Net loss	$ (13,878,027)	$ (10,540,477)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	728,828	299,409
Accretion of discount on NuvoGen obligation	104,467	177,751
Bad debt expense, net of recoveries		33,854
Provision for excess inventory	149,763	210,881
Amortization of Growth Term Loan discount and issuance costs	267,047	181,061
Loss on settlement of convertible notes		705,217
Amortization of discount on convertible notes		90,222
Stock-based compensation expense	322,136	146,548
Change in redeemable convertible preferred stock warrant liability	0	239,683
Accretion of incentive from landlord	(59,165)
Accrued interest on available-for-sale securities investments	125,138
Loss on disposal of assets		70,626
Changes in operating assets and liabilities:
Accounts receivable	(1,195,148)	213,090
Inventory	(161,570)	(937,160)
Prepaid expenses and other	(228,723)	(657,054)
Accounts payable	799,786	7
Accrued liabilities	(42,404)	(418,392)
Deferred revenue	136,231	(12,495)
Net cash used in operating activities	(12,931,641)	(10,197,229)
Investing activities
Purchase of property and equipment	(1,620,946)	(444,329)
Sales, redemptions and maturities of available-for-sale securities	18,700,000	(32,877,808)
Purchase of available-for-sale securities	(3,381,271)
Net cash provided by (used in) investing activities	13,697,783	(33,322,137)
Financing activities
Proceeds from initial public offering		47,654,190
Deferred offering costs		(1,002,930)
Proceeds from Growth Term Loan	5,000,000
Payments on Growth Term Loan	(1,450,576)
Proceeds from convertible notes		4,500,000
Deferred convertible note financing costs		(75,523)
Payments on capital leases	(66,706)	(14,622)
Proceeds from exercise of stock options	2,142	5,578
Proceeds from exercise of Series E warrants		8,948
Proceeds from issuance of convertible note warrants		1,354
Proceeds from shares purchased under the stock purchase plan	146,758
Payments on NuvoGen obligation	(181,250)
Net cash provided by financing activities	3,450,368	51,076,995
Increase in cash and cash equivalents	4,216,510	7,557,629
Cash and cash equivalents at beginning of period	3,293,983	3,613,392
Cash and cash equivalents at end of period	7,510,493	11,171,021
Noncash investing and financing activities
Accretion of preferred stock issuance costs		35,046
Accretion of dividends		1,165,932
Deferred offering costs reclassified to distributions in excess of capital		2,297,079
Allocation of Series E warrant convertible notes debt discount		741,828
Conversion of convertible notes and related accrued interest to common stock		4,544,384
Reclassification of convertible preferred stock liability warrants to equity warrants		(1,616,140)
Fixed asset purchases payable and accrued at period end	214,033	244,350
Stock issued for settlement of accrued bonus	(364,910)
Purchase of property and equipment under capital lease	209,588
Incentive from landlord	710,000
Supplemental cash flow information
Cash paid for interest	$ 559,832	467,500
Common Stock
Noncash investing and financing activities
Conversion of convertible preferred stock to common stock		(57,356,049)
Series D And E Redeemable Convertible Preferred Stock
Noncash investing and financing activities
Accretion of dividends		1,165,932
Series D and Series E Warrants
Noncash investing and financing activities
Exercise of warrants		(95,914)
Series E Warrants
Noncash investing and financing activities
Accretion of warrant discount		$ 127,616